MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma
Open Access
- 14 May 2012
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (10), 2828-2837
- https://doi.org/10.1158/1078-0432.ccr-12-0160
Abstract
Purpose: Pheochromocytomas (PCC) and paragangliomas (PGL) are genetically heterogeneous neural crest–derived neoplasms. Recently we identified germline mutations in a new tumor suppressor susceptibility gene, MAX (MYC-associated factor X), which predisposes carriers to PCC. How MAX mutations contribute to PCC/PGL and associated phenotypes remain unclear. This study aimed to examine the prevalence and associated phenotypic features of germline and somatic MAX mutations in PCC/PGL. Design: We sequenced MAX in 1,694 patients with PCC or PGL (without mutations in other major susceptibility genes) from 17 independent referral centers. We screened for large deletions/duplications in 1,535 patients using a multiplex PCR-based method. Somatic mutations were searched for in tumors from an additional 245 patients. The frequency and type of MAX mutation was assessed overall and by clinical characteristics. Results: Sixteen MAX pathogenic mutations were identified in 23 index patients. All had adrenal tumors, including 13 bilateral or multiple PCCs within the same gland (P < 0.001), 15.8% developed additional tumors at thoracoabdominal sites, and 37% had familial antecedents. Age at diagnosis was lower (P = 0.001) in MAX mutation carriers compared with nonmutated cases. Two patients (10.5%) developed metastatic disease. A mutation affecting MAX was found in five tumors, four of them confirmed as somatic (1.65%). MAX tumors were characterized by substantial increases in normetanephrine, associated with normal or minor increases in metanephrine. Conclusions: Germline mutations in MAX are responsible for 1.12% of PCC/PGL in patients without evidence of other known mutations and should be considered in the genetic work-up of these patients. Clin Cancer Res; 18(10); 2828–37. ©2012 AACR.Keywords
Other Versions
This publication has 34 references indexed in Scilit:
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of PheochromocytomaClinical Chemistry, 2011
- Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor LocationJournal of Clinical Endocrinology & Metabolism, 2011
- Catecholamine metabolomic and secretory phenotypes in phaeochromocytomaEndocrine-Related Cancer, 2010
- SDHA is a tumor suppressor gene causing paragangliomaHuman Molecular Genetics, 2010
- Germline mutations in TMEM127 confer susceptibility to pheochromocytomaNature Genetics, 2010
- The Warburg Effect Is Genetically Determined in Inherited PheochromocytomasPLOS ONE, 2009
- SDH5 , a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in ParagangliomaScience, 2009
- Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2Journal of Clinical Endocrinology & Metabolism, 2009
- A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in PheochromocytomasPLoS Genetics, 2005